ViralClear to Host Conference Call on June 9th to Discuss Upcoming and Recent Developments for Phase II Human Clinical Trials...
June 01 2020 - 10:42AM
- Company to provide updates on the initiation of human
trials for treatment of adult hospitalized patients with
COVID-19
- Phase II clinical trial will be conducted with
merimepodib and remdesivir in multiple sites nationwide with
data expected in the third quarter 2020
BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the
“Company”) and its subsidiary, ViralClear Pharmaceuticals, Inc.,
today announced that it will host a call to discuss the Phase II
clinical trials of merimepodib, its broad-spectrum oral anti-viral
candidate for the treatment of COVID-19 in adult patients.
The format will be a management presentation updating recent
developments followed by a Q&A session with select call
attendees.
Conference Call Details:Date: Tuesday, June 9,
2020Time: 11:00 AM Eastern Time (ET)Dial in Number for U.S.
Callers: 1-877-407-8293Dial in Number for International Callers:
1-201-689-8349
A replay will be available for two weeks starting on June 9,
2020 at approximately 2:00 PM ET. To access the replay, please dial
1-877-660-6853 in the U.S. and 1-201-612-7415 for international
callers. The conference ID# is 13704617.
On May 14, 2020, an article titled, "The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro" was published by F1000 Research, an online peer-reviewed
life sciences journal publishing program in biology and medicine.
The article cites that merimepodib in combination with remdesivir
decreases viral production of SARS-CoV-2 to undetectable levels in
pre-clinical testing.
On May 18, 2020, ViralClear announced the FDA’s clearance of its
IND to proceed with a proposed Phase II study of merimepodib in
COVID-19 patients. The human clinical trial is planned to be
conducted under the leadership of Dr. Andrew D. Badley, Professor
and Chair of the Department of Molecular Medicine and the
Enterprise Chair of the COVID-19 Task Force at Mayo Clinic.
About BioSig Technologies BioSig Technologies
is a medical technology company commercializing a proprietary
biomedical signal processing platform designed to improve signal
fidelity and uncover the full range of ECG and intra-cardiac
signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About Merimepodib (MMPD) Merimepodib, a
broad-spectrum anti-viral candidate, has demonstrated strong
activity against COVID-19 in cell cultures in laboratory
testing. Merimepodib was previously in development as a
treatment for chronic hepatitis C and psoriasis by Vertex
Pharmaceuticals Incorporated (Vertex), with 12 clinical trials
conducted (including 315 chronic hepatitis C patients, 24 psoriasis
patients, and 98 healthy volunteers) and an extensive preclinical
safety package completed.
A manuscript titled, “The IMPDH inhibitor merimepodib provided
in combination with the adenosine analogue remdesivir reduces
SARS-CoV-2 replication to undetectable levels in vitro”, was
submitted to an online peer-reviewed life sciences journal. This
manuscript is authored by Natalya Bukreyeva, Rachel A. Sattler,
Emily K. Mantlo, John T. Manning, Cheng Huang and Slobodan Paessler
of the UTMB Galveston National Laboratory and Dr. Jerome Zeldis of
ViralClear Pharmaceuticals, Inc. (“ViralClear”) as a corresponding
author. This article highlights pre-clinical data generated under
contract with Galveston National Laboratory at The University of
Texas Medical Branch.
About ViralClear BioSig’s subsidiary,
ViralClear Pharmaceuticals, Inc., is seeking to develop a novel
pharmaceutical to treat COVID-19. Merimepodib is intended to be
orally administered, and has demonstrated broad-spectrum in vitro
antiviral activity, including strong activity against COVID-19 in
cell cultures. Merimepodib has been previously studied in 12
clinical trials, including 5 in patients with hepatitis C (1 Phase
1b, 1 Phase 2, 2 Phase 2a, and 1 Phase 2b), 1 in patients with
psoriasis (Phase 2), and six in healthy volunteers (Phase I).
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024